TG Therapeutics 的 BRIUMVI 由 Neuraxpharm Group 在欧洲推出，用于治疗复发性多发性硬化症，首先从德国开始。 TG Therapeutics' BRIUMVI launched in Europe by Neuraxpharm Group for relapsing multiple sclerosis treatment, starting in Germany.

TG Therapeutics 宣布其前美国合作伙伴 Neuraxpharm Group 在欧洲推出 BRIUMVI (ublituximab-xiiy)，用于治疗成人复发型多发性硬化症 (RMS)。 TG Therapeutics announced the European launch of BRIUMVI (ublituximab-xiiy) by its ex-US partner, Neuraxpharm Group, for the treatment of adults with relapsing forms of multiple sclerosis (RMS). 该活动从德国开始，并将扩展到整个欧洲。 The launch began in Germany and will expand throughout Europe. TG Therapeutics 将因 BRIUMVI 首次在欧洲上市而获得 1250 万美元的里程碑付款。 TG Therapeutics will receive a $12.5M milestone payment for the first European launch of BRIUMVI. 这标志着欧洲患者的重大突破。 This marks a significant breakthrough for patients in Europe.